Leading Pharmaceutical Company Selects Dendrite to Promote Patient Adherence across its Enterprise
August 09 2006 - 8:00AM
Business Wire
Dendrite International, Inc. (NASDAQ:DRTE) a leading provider of
pharmaceutical industry solutions, today announced that one of the
world's leading pharmaceutical companies has selected Dendrite to
orchestrate patient adherence programs for all participating
brands. The company's decision was based on Dendrite's complete
approach to patient adherence management, an escalating priority
across the US pharmaceutical industry, as companies seek to close
the gap between prescribed therapy and actual patient behavior.
Three critical strengths underpin Dendrite's comprehensive patient
adherence offering. First, the Dendrite solution reaches an
expansive pharmacy network, with access to approximately 98 percent
of the major retail pharmacies in the U.S. Second, Dendrite's
reporting and analytics capabilities add more precision to a
pharmaceutical company's marketing programs, offering unrivaled
depth and breadth of insight on program effectiveness across
multiple channels and messages. Finally, Dendrite has the unique
ability to deliver communications across multiple channels, based
on prescriber and patient preference. "According to recent data,
between 15-25 percent of total prescriptions remain unfilled.
Moreover, approximately 30-40 percent of patients never refill a
prescription despite the orders of their physician," said Carl
Cohen, president of Dendrite's Marketing Solutions division. "This
kind of behavior can potentially cause serious harm to a patient
who disregards his or her drug regimen, while also placing a
significant strain on the healthcare system. Dendrite's goal is to
add more precision to pharmaceutical marketing programs through
more closely targeted, tightly orchestrated, multi-channel
campaigns that ultimately leads to better patient outcomes." About
Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE)
enables sales, marketing, clinical and compliance solutions for the
global pharmaceutical industry. The Company's clients are located
in more than 50 countries and include the world's top 20
pharmaceutical companies. For more information, please visit
www.dendrite.com. Note: Dendrite is a registered trademark of
Dendrite International, Inc. This document may contain
forward-looking statements that may be identified by such
forward-looking terminology as "expect," "believe," "anticipate,"
"will," "intend," "plan," "target," "outlook," "guidance," and
similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties,
including risks which may result from our dependence on the
pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our
solutions; our fixed expenses in relation to fluctuating revenues
and variations in customers' budget cycles; dependence on certain
major customers; changes in demand for our products and services
attributable to any weakness experienced in the economy or mergers,
acquisitions and consolidations in the pharmaceutical industry;
successful and timely development and introduction of new products
and versions; rapid technological changes; increased competition;
international operations; integrating the entities we acquire; our
ability to effectively manage our growth; the protection of our
proprietary technology; our ability to compete in the
Internet-related products and services market; the continued demand
for Internet-related products and services; the ability of our
third party vendors to respond to technological change; our ability
to maintain our relationships with third-party vendors; less
favorable than anticipated results from strategic relationships;
dependence of data solutions on strategic relationships; events
which may affect the U.S. and world economies; and catastrophic
events which could negatively affect our information technology
infrastructure. Other important factors that should be reviewed and
carefully considered are included in the company's 10-K, 10-Qs, and
other reports filed with the SEC. Actual results may differ
materially. The company assumes no obligation for updating any such
forward-looking statements to reflect actual results, changes in
assumptions or other changes affecting such forward-looking
statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024